TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17261601
Drug: LT vaccine
Normalized name: hepatitis A adult vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT vaccine patch (50 microg) administered on days 0 and 21
Study: 17261601
Drug: Oral ETEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ETEC challenge (LT+ ST+ E2447A)
Study: 17261601
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera toxin B subunit-containing cholera vaccine
Study: 15059332
Drug: Stenting followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stenting followed by radiotherapy and/or chemotherapy (Group B, n = 26)
Study: 15059332
Drug: Stenting followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stenting followed by radiotherapy and/or chemotherapy (Group B)
Study: 11224828
Drug: Oseltamivir 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 2 mg/kg/dose twice daily for 5 days
Study: 8968633
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy with ritual prevention
Study: 6776577
Drug: Combined alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined alcohol + tobacco (4 cigarettes + 0.65 g/kg ethyl alcohol)
Study: 22748849
Drug: Fibrin-based biological
Normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin-based biological adhesive applied to the suture line
Study: 10404769
Drug: E2 (2
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 (2 mg micronised oestradiol daily)
Study: 8803649
Drug: Fluvoxamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (up to 150 mg/day as a single bedtime dose)
Study: 8803649
Drug: Imipramine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (240 mg/day on a twice‐daily schedule)
Study: 24668660
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg for normal/mildly impaired renal function
Study: 24668660
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg for moderate renal impairment
Study: 17989110
Drug: Pharmacogenetic-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic-guided dosing (wild-type patients)
Study: 17989110
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (wild-type patients)
Study: 17989110
Drug: Pharmacogenetic-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic-guided dosing (multiple variant carriers)
Study: 17989110
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (multiple variant carriers)
Study: 16301267
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve blockade (CFNB) with bupivacaine 0.2% (median infusion rate 9.3 mL/h)
Study: 16301267
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia (CEA) with ropivacaine 0.2% and fentanyl 4 microg/mL (median infusion rate 7.6 mL/h)
Study: 391342
Drug: Trimipramine (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (tricyclic antidepressant; mean dose 106 mg at night)
Study: 391342
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors (MAOIs; phenelzine mean dose 45 mg/day, isocarboxazid mean dose 32 mg/day)
Study: 391342
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (phenelzine plus trimipramine or isocarboxazid plus trimipramine)
Study: 30282088
Drug: Tissue-level implants
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-level implants restored by platform matching (control)
Study: 30282088
Drug: Bone-level implants
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-level implants restored by platform switching (test)
Study: 16928616
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary podocyte mRNA excretion
Study: 14769712
Drug: Amiodarone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone, 200 mg/d
Study: 14769712
Drug: Propafenone, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone, 450 mg/d
Study: 11379374
Drug: Synthetic conjugated
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic conjugated estrogen tablets
Study: 9135227
Drug: Alendronate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (7.5 mg dissolved in 250 ml saline solution)
Study: 9135227
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline infusions
Study: 9135227
Drug: Alendronate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (7.5 mg/day for three days, open label)
Study: 7955026
Drug: High-titre measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre measles vaccine (EZ-HT, SW-HT)
Study: 3680601
Drug: Caffeine (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (64 mg) + Aspirin (800 mg)
Study: 3680601
Drug: Caffeine (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (64 mg)
Study: 3680601
Drug: Aspirin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (800 mg)
Study: 28064163
Drug: Spironolactone 12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 12.5-50 mg/day
Study: 27917793
Drug: i.v. furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. furosemide (200‐300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day)
Study: 27917793
Drug: oral furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral furosemide tablets (360‐520 mg bid) and salt (2.5 g bid)
Study: 27917793
Drug: repeated large‐volume‐paracentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeated large‐volume‐paracentesis (RLVP) with albumin infusion
Study: 24873894
Drug: Soybean leaf
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean leaf extracts (SLE) 2 g per day
Study: 24873894
Drug: Banaba extracts
Normalized name: banana extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banaba extracts (BE) 300 mg per day
Study: 24873894
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch 2 g per day)
Study: 15756156
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: midazolam (0.015‐0.030 mg/kg) and sufentanil (0.15‐0.20 microg/kg)
Study: 15756156
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: midazolam (0.15‐0.2 mg/kg) and continuous remifentanil infusion 0.5‐1 microg/kg/min followed by 0.05 microg/kg/min
Study: 7670590
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of prostaglandin E1 with RMRI penile clamp
Study: 7670590
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of prostaglandin E1 without RMRI penile clamp
Study: 31816191
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 1:100,000 epinephrine injected intranasally
Study: 31816191
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 1:200,000 epinephrine injected intranasally
Study: 31816191
Drug: Topical 1:1000
Normalized name: thimerosal topical 1:1000 topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1:1000 epinephrine pledgets placed after injection of epinephrine
Study: 23150678
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 4, 8, and 40 mU/m2 · min during a three-stage hyperinsulinemic/euglycemic clamp after dietary control and overnight insulin infusion.
Study: 21770925
Drug: USL255 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL255 (200 mg) in fasted conditions
Study: 21770925
Drug: USL255 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL255 (200 mg) in fed conditions
Study: 21770925
Drug: Topamax (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topamax (100 mg) administered 12 h apart
Study: 19325515
Drug: Praziquantel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (75 mg/kg/d for 1 day) with albendazole (15 mg/kg/d for 7 days)
Study: 19325515
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/d for 7 days)
Study: 17661565
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation (control for infants)
Study: 14974311
Drug: 90 ml
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 ml sodium phosphate with an additional 2.5 litres of fluid
Study: 14974311
Drug: Combined PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PEG solutions (PEG 4000 and PEG 3350)
Study: 10771930
Drug: Regular transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular transfusion therapy
Study: 30630184
Drug: Round window
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round window niche drilling combined with daily intratympanic methylprednisolone for 7 times
Study: 30630184
Drug: Daily intratympanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intratympanic methylprednisolone for 7 times
Study: 23953030
Drug: Irinotecan 3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 3-weekly 350 mg/m² (or 300 mg/m² if age >70 or performance status (PS)=2)
Study: 23953030
Drug: Irinotecan 3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 3-weekly 140 mg/m² (120 mg/m² if age >70 or PS=2) with ciclosporin 3 mg/kg t.d.s. for three days by mouth starting on the morning before irinotecan
Study: 21050027
Drug: Nasal budesonide
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal budesonide 100 μg, 1 puff per nostril twice a day
Study: 15640636
Drug: Inhaled isoflurane
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoflurane via the Anesthetic Conserving Device
Study: 15640636
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam infusion
Study: 11699174
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching agent (Opalescence/Ultradent)
Study: 9159691
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin eyedrops
Study: 30730938
Drug: Daily power
Normalized name: ZO SKIN HEALTH OSSENTIAL DAILY POWER DEFENSE ANTI-AGING FORMULA and OCLIPSE SUNSCREEN PLUS PRIMER BROAD SPECTRUM SPF 30 UVA/UVB PROTECTION KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily power posing practice
Study: 23686706
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1,000 mg)
Study: 21160218
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine 1.5 mg · kg(‐1) administered into the deltoid muscle 10 min before anaesthesia induction
Study: 21160218
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg · kg(‐1), 2 min before anaesthesia induction
Study: 21160218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only propofol injection
Study: 15726852
Drug: CTiP-fabricated frameworks
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTiP-fabricated frameworks directly to Brånemark implants
Study: 15726852
Drug: Brånemark implant/abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brånemark implant/abutment assemblies
Study: 11768928
Drug: Analgesics, tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics, tricyclic antidepressants, and other agents
Study: 23690420
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus radiation therapy (TamRT)
Study: 20953559
Drug: Topical quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical quercetin applied two to three dabs three times daily
Study: 20953559
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride mouthwash used three times daily
Study: 16884341
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (twice weekly for 12 weeks)
Study: 16884341
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (friendly visit, twice weekly for 12 weeks)
Study: 8841224
Drug: One E2
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One E2 transdermal system
Study: 8841224
Drug: Two E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two E2 transdermal systems
Study: 8841224
Drug: E2 transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 transdermal system
Study: 6383908
Drug: i.v. group
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. group (insulin by continuous intravenous infusion)
Study: 6383908
Drug: s.c. group
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. group (conventional subcutaneous therapy)
Study: 22466349
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg twice daily for 5 weeks)
Study: 22466349
Drug: Estradiol (100-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (100-μg patch daily for 5 weeks)
Study: 20227097
Drug: Retention sutured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention sutured sequential fascial closure (RSSFC)
Study: 18709009
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (exposition, occlusive dressing, initial excision with skin grafting)
Study: 15753413
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIG) 0.4 g/kg body weight, administered at days 0, 1, 2, 30, and 60
Study: 8971505
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further oncologic treatment).
Study: 27206648
Drug: Ibuprofen pretreatment
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen pretreatment (800 mg) before catheterization (cohort 3)
Study: 22126622
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education program targeting oral malodor prevention
Study: 20123877
Drug: Extraoral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 20123877
Drug: Intraoral infraorbital
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 12120905
Drug: Methotrexate once
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate once weekly
Study: 12120905
Drug: Methotrexate twice
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate twice weekly
Study: 12120905
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (once weekly and twice weekly)
Study: 10451039
Drug: Eprosartan 400
Normalized name: eprosartan 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 400 mg total daily dose (b.i.d.), increased to 600 and 800 mg if necessary
Study: 10451039
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg total daily dose (o.d.), increased to 20 and 40 mg if necessary
Study: 21668768
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg)
Study: 28652463
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model of insulin resistance
Study: 25872567
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral curcumin at the target dose determined in Phase I
Study: 25872567
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care oxaliplatin-based chemotherapy alone
Study: 30642738
Drug: Oral citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citrulline supplementation
Study: 29952809
Drug: Pulmonary Rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary Rehabilitation plus Oral Nutritional Supplement (PRONS) for 12 weeks
Study: 15523452
Drug: Dextromethorphan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (1 mg/kg)
Study: 16083921
Drug: Methylphenidate (Ritalin)
Normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (Ritalin) treatment
Study: 12679222
Drug: S 18886
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 18886 (10 mg single oral dose)
Study: 3605567
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg/kg
Study: 23144450
Drug: Pegloticase treatment
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase treatment
Study: 24649935
Drug: 830 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 830 nm low-level laser therapy (LLLT) administered five times per week for 2 weeks (average power 60 mW, peak power 8 W, 10 Hz, 600 sec, and 9.7 J/cm² per fracture site)
Study: 24649935
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received sham laser treatment
Study: 22647618
Drug: PLP-dependent disturbances
Normalized name: PLP
DrugBank: Pyridoxal phosphate (DB00114)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PLP-dependent disturbances of tryptophan metabolism
Study: 17852064
Drug: Stop Using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop Using Stuff (SUS) - a brief cognitive behavioural therapy (CBT) intervention, 4 to 6 sessions
Study: 12206443
Drug: 9-month exercise
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month exercise intervention (goal: at least 10 miles of weekly brisk walking or jogging)
Study: 1657656
Drug: 10.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g/day dietary fibre
Study: 1657656
Drug: 21 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 g/day dietary fibre
Study: 7117309
Drug: L-dopa and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa and/or physostigmine treatment
Study: 30357263
Drug: DHA+AA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+AA (200 mg DHA and 200 mg AA daily for 6 months)
Study: 27693978
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture plus fluoxetine (n=22)
Study: 27693978
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus fluoxetine (n=24)
Study: 23949801
Drug: Low-glucose regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glucose regimen (combination of dextrose-based solution, icodextrin and amino acids)
Study: 23949801
Drug: Dextrose solutions
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solutions only (control group)
Study: 16142502
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or antiresorptive drugs (including hormone replacement therapy and alendronate)
Study: 14727367
Drug: Oral antiphlogistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiphlogistic medicinal granules only (Group A)
Study: 14727367
Drug: Oral antiphlogistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiphlogistic medicinal granules + retention enema (Group B)
Study: 14727367
Drug: Oral antiphlogistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiphlogistic medicinal granules + rectal (Group C)
Study: 11527612
Drug: Eptifibatide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (two 180 microg/kg boluses 10 min apart and continuous infusion of 2 microg/kg per min)
Study: 9547132
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg once a day, titrated to a maximum of 200 mg)
Study: 9547132
Drug: Sertraline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (2 full years treatment)
Study: 9547132
Drug: Sertraline (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (during double-blind phase)
Study: 27194317
Drug: Nurse-led lymphoma
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led lymphoma survivorship clinic with three face-to-face appointments and tailored resources, survivorship care plan and treatment summary (SCP TS).
Study: 27194317
Drug: Usual post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Usual post-treatment care.